靶点- |
作用机制- |
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
A Prospective Study Assessing the Relationship Between Expression of the Norepinephrine Transporter and 18F-mFBG PET Imaging Results in Neuroblastoma Tumor, Other Neural Crest Tumors, and Organs Innervated by the Sympathetic Nervous System
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter. In addition to collecting safety data for the imaging agent, the study aims to:
compare the findings against other catacholamine transporters
evaluate the imaging results at different time points and in different organs
assess the quality of images with lower doses
compare the ability to detect neuroblastoma lesions against other imaging agents, and in other tumors
A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects With Neuroblastoma
This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma
An Open-Label, Exploratory, Phase 1/2 Scintigraphy Study Evaluating 18F-mFBG for Imaging Myocardial Sympathetic Innervation in Subjects Without and With Heart Disease
This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.
100 项与 Illumina Radiopharmaceuticals LLC 相关的临床结果
0 项与 Illumina Radiopharmaceuticals LLC 相关的专利(医药)
100 项与 Illumina Radiopharmaceuticals LLC 相关的药物交易
100 项与 Illumina Radiopharmaceuticals LLC 相关的转化医学